On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


One World Holdings (OWOO) Releases Preview of New Prettie Girls! Tween Scene Story Book

The One World Doll Project, subsidiary of One World Holdings, Inc. (OTC:OWOO), this morning on the company’s website (oneworlddolls.com/books) released a sneak peek preview of its new Prettie Girls! Tween Scene story book.

The first line of Prettie Girls! Tween Scene story books will feature a different story for each of the Tween Scene dolls, as well as a general story book that will introduce readers to the Tween Scene girls and their individual traits and characteristics.

The launch of the book coincides with the company’s recent distribution agreement with Wal-Mart (NYSE:WMT) and supports the company’s expansion initiatives.

“Now that the company has secured a major retail distribution deal with Walmart, we are focusing on maximizing the value of the Prettie Girls! brand by developing ancillary products and these story books are perfect for brand exposure to early adopters,” Trent T. Daniel, founder of The One World Doll Project, stated in the news release.

Established in 2010 by Daniel and Stacey McBride-Irby, The One World Doll Project is committed to changing the retail landscape of the doll industry through its Prettie Girls!™, a collection of fashion play dolls diverse in culture, interests and style.

For more information, visit www.oneworlddolls.com

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.